Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early
Prostate Cancer News Today
by Marisa Wexler MS
3y ago
Understanding the molecular components of odors used by trained dogs to detect prostate cancer could help researchers to develop computers with similar diagnostic accuracy, a new study shows. The study, “Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer,” was published in PLOS One. An ongoing need in prostate cancer care is for more accurate non-invasive tests to detect the cancer, and to distinguish between potentially deadly tumors and benign growths. Currently, the most common approach is to measure levels of t ..read more
Visit website
Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT
Prostate Cancer News Today
by Marta Figueiredo
3y ago
Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk disease will benefit from adding androgen deprivation therapy (ADT) to standard radiation therapy, a study shows. This Myriad Genetics’ test was found to be superior to other methods at predicting cancer spread (metastasis) in these patients, and thereby at distinguishing those who could avoid ADT. The findings, “Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate ca ..read more
Visit website
Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports
Prostate Cancer News Today
by Forest Ray PhD
3y ago
Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs of disease worsening, compared with Zytiga alone, Janssen announced in a press release. Findings from the ACIS Phase 3 trial (NCT02257736), which enrolled patients on androgen deprivation therapy (ADT) who had not been treated with chemotherapy, also showed that the combination led to stronger responses and a trend toward better overall survival. Trial’s findings were presented in the oral presen ..read more
Visit website
Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening
Prostate Cancer News Today
by Joana Carvalho
3y ago
When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — without compromising their quality of life — according to final data from a Phase 3 trial. Findings from the study, called TITAN (NCT02489318), also showed that the combination treatment significantly delayed disease progression or death among trial participants, according to Johnson & Johnson, the therapy’s developer. The combo therapy also delayed the time to castration resistance, or a tumor’s res ..read more
Visit website
‘TRUE Love’ Contest Calls for Entries Honoring Caregivers
Prostate Cancer News Today
by Mary Chapman
3y ago
With help from actress Kristen Bell, the Prostate Cancer Foundation (PCF) has opened its 4th annual TRUE Love contest for entries that pay tribute to family members and caregivers of men living with prostate cancer. The organization is seeking caregiving narratives that show love, care, and honor for prostate cancer patients to raise awareness about a disease that affects one in eight men. The contest deadline is March 7, and winners will be notified a week later. “The comfort and care that dedicated caregivers provide is inspiring and truly heroic, especially this past year throughout the p ..read more
Visit website
New AI Tool May Better Predict Relapse After Surgery
Prostate Cancer News Today
by Marta Figueiredo
3y ago
Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called RadClip, for radiomic-clinicopathologic nomogram, the tool was developed by a team from the Center for Computational Imaging and Personalized Diagnostics (CCIPC) at Case Western Reserve University. Its validation was described in a study titled “A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from ..read more
Visit website
Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer
Prostate Cancer News Today
by Diana Campelo Delgado
3y ago
Dosing has begun in a Phase 1 clinical trial testing Forma Therapeutics’ investigational therapy FT-7051 in people with metastatic castration-resistant prostate cancer (mCRPC). Recruiting at sites in Arizona and South Carolina, the open-label trial (NCT04575766) is expected to enroll 45 patients who failed to respond to at least one potent anti-androgen treatment. Contact and site information can be found here. “Initiating enrollment in this Phase 1 trial is an important step toward our goal of providing mCRPC patients with an additional therapeutic option to treat this severe illness ..read more
Visit website
NBA Teams Join Efforts to Raise Money and Awareness
Prostate Cancer News Today
by Forest Ray PhD
3y ago
The Prostate Cancer Foundation (PCF) and several NBA teams are joining efforts to raise money and awareness for prostate cancer research throughout February. Various national basketball teams, including the Atlanta Hawks, Chicago Bulls, and Phoenix Suns, are taking part in the Third Annual PCF Black History Month Assist Challenge. “We are thrilled and honored that NBA teams have again joined our efforts in reaching out to save men’s lives,” Christine Jones, PCF’s chief operating officer, said in a press release. In 2019, the Atlanta Hawks became the first NBA team to participate in the chall ..read more
Visit website
Biological Clock Protein CRY-1 Eyed as Therapeutic Target
Prostate Cancer News Today
by Steve Bryson PhD
3y ago
CRY-1, a regulator of our circadian clocks, contributes to disease spread and poor outcomes in prostate cancer patients by boosting DNA repair mechanisms that render cells more resistant to treatments, a study reveals. The findings support further investigation of CRY-1 as a therapeutic target, especially in prostate cancers that fail to respond to current therapies.  The study, “The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair,” was published in the journal Nature Communications.  Male androgen hormones, such as testosterone ..read more
Visit website
EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients
Prostate Cancer News Today
by Diana Campelo Delgado
3y ago
Essa Pharma has entered a clinical collaboration with Janssen to evaluate its small molecule inhibitor EPI-7386, in combination with either Erleada (apalutamide) or Zytiga (abiraterone acetate) plus prednisone, for patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the agreement, Janssen will conduct up to two Phase 1/2 clinical trials evaluating these combinations in people who failed second-generation androgen receptor inhibitors such as Erleada or Zytiga. A joint committee from both companies will oversee the trials, which are expected to begin ..read more
Visit website

Follow Prostate Cancer News Today on FeedSpot

Continue with Google
Continue with Apple
OR